一次性進行型多発性硬化症(Primary Progressive Multiple Sclerosis (PPMS))：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Primary Progressive Multiple Sclerosis (PPMS) Overview 6
Therapeutics Development 7
Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) – Overview 7
Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) – Comparative Analysis 8
Primary Progressive Multiple Sclerosis (PPMS) – Therapeutics under Development by Companies 9
Primary Progressive Multiple Sclerosis (PPMS) – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Primary Progressive Multiple Sclerosis (PPMS) – Products under Development by Companies 13
Primary Progressive Multiple Sclerosis (PPMS) – Companies Involved in Therapeutics Development 14
AB Science 14
Genzyme Corporation 15
Glialogix, Inc. 16
Innate Immunotherapeutics Limited 17
Kyorin Pharmaceutical Co., Ltd. 18
MedDay 19
Santhera Pharmaceuticals Holding AG 20
Teva Pharmaceutical Industries Limited 21
Primary Progressive Multiple Sclerosis (PPMS) – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
GLX-1112 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GZ-402668 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ibudilast – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
idebenone – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
laquinimod sodium – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
masitinib – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MD-1003 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MIS-416 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules for Multiple Sclerosis – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Primary Progressive Multiple Sclerosis (PPMS) – Recent Pipeline Updates 49
Primary Progressive Multiple Sclerosis (PPMS) – Discontinued Products 68
Primary Progressive Multiple Sclerosis (PPMS) – Product Development Milestones 69
Featured News & Press Releases 69
Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 69
Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71